|

Letrozole 2.5mg Clinical Trials

10 actively recruiting trials across 2 locations

Also known as: Clomiphene Citrate, Femara, Letrozole

Pipeline

Phase 2: 3Phase 3: 2Phase 4: 1Phase 2/3: 2

Top Sponsors

  • Xiaojun Chen2
  • wanghaibo1
  • Yale University1
  • University of California, San Francisco1
  • Swiss GO Trial Group1

Indications

  • Cancer10
  • Breast Cancer3
  • Progesterone Resistance2
  • Atypical Endometrial Hyperplasia2
  • Endometrial Neoplasms2

Other8 trials

Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism
N/A
Combination Letrozole and Clomiphene Citrate Versus Letrozole Alone
N/A
Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer
Phase 2
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
Phase 3
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
Phase 2/3
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
Phase 2/3
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
Phase 2
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Phase 3

Los Angeles, California1 trial

Prescription of Letrozole for Uterine Myoma

University of California, Los Angeles

Phase 4

New Haven, Connecticut1 trial

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Yale University

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.